Key Developments: Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

102.20USD
23 Jan 2015
Change (% chg)

$-1.56 (-1.50%)
Prev Close
$103.76
Open
$102.90
Day's High
$102.92
Day's Low
$101.94
Volume
2,847,447
Avg. Vol
2,467,021
52-wk High
$109.49
52-wk Low
$86.09

Search Stocks

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson gives FY 2015 EPS outlook in line with analysts' estimates
Tuesday, 20 Jan 2015 07:45am EST 

Johnson & Johnson:Expects FY 2015 adjusted earnings guidance in the range of $6.12 to $6.27 per share.FY 2015 EPS of $6.13 - Thomson Reuters I/B/E/S.  Full Article

Johnson & Johnson announces start of phase 1 clinical trial of ebola vaccine regimen
Tuesday, 6 Jan 2015 02:00am EST 

Johnson & Johnson:Says start of a Phase 1, first-in-human clinical trial of preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies.Says trial is being led by Oxford Vaccine Group, part of University of Oxford Department of Paediatrics.Says recruitment in trial is underway, and first volunteers have received their initial vaccine dose.Enrollment is expected to be completed by end of Jan.Also said that Janssen, in partnership with Bavarian Nordic A/S, has produced more than 400,000 regimens of prime-boost vaccine for use in large-scale clinical trials by April 2015.Says total of 2 mln regimens will be available through course of 2015, with the ability to quickly scale up to 5 mln regimens, if required, over 12- to 18-month period.Says this increased projection is an update to Janssen's previous goal of producing more than 1 mln regimens by end of 2015, with 250,000 regimens for broad application in clinical trials by May 2015.  Full Article

Johnson & Johnson announces quarterly dividend for first quarter 2015
Monday, 5 Jan 2015 08:45am EST 

Johnson & Johnson:Declares a cash dividend for the first quarter of 2015 of $0.70 per share on the company's common stock.Payable on March 10 to shareholders of record at the close of business on Feb. 24.  Full Article

Johnson & Johnson announces completion of Alios BioPharma acquisition
Friday, 7 Nov 2014 04:05pm EST 

Johnson & Johnson:Announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of about $1.75 billion in cash.With this acquisition complete, Alios BioPharma will now become part of the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson.Acquisition includes Alios BioPharma's portfolio of potential therapeutics for viral infections with the promising compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus.  Full Article

Johnson & Johnson announces quarterly dividend for Q4 2014
Thursday, 16 Oct 2014 07:44am EDT 

Johnson & Johnson:Says Board has declared a cash dividend for the Q4 2014 of $0.70 per share on its common stock.Says dividend is payable on Dec. 9, to shareholders of record at the close of business on Nov. 25.  Full Article

Johnson & Johnson raises FY 2014 earnings guidance
Tuesday, 14 Oct 2014 07:45am EDT 

Johnson & Johnson:Increased FY 2014 earnings guidance to $5.92 - $5.97 per share.Says guidance excludes the impact of special items.FY 2014 EPS of $5.93 - Thomson Reuters I/B/E/S.  Full Article

Johnson & Johnson announces agreement to acquire Alios BioPharma
Tuesday, 30 Sep 2014 08:30am EDT 

Johnson & Johnson:Announces definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for about $1.75 billion in cash.The acquisition will include Alios BioPharma's portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus.The transaction is expected to close during the fourth quarter of 2014.  Full Article

Johnson & Johnson announces $5 bln share repurchase program
Monday, 21 Jul 2014 05:00pm EDT 

Johnson & Johnson:Approves the repurchase of up to $5 billion of the company's common stock.Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions.  Full Article

Johnson & Johnson announces quarterly dividend for third quarter 2014
Monday, 21 Jul 2014 11:10am EDT 

Johnson & Johnson:Declares cash dividend for third quarter of 2014 of $0.70 per share on the company's common stock.Dividend is payable on Sept. 09, 2014 to shareholders of record at the close of business on Aug. 26, 2014.Ex-dividend date is Aug. 22, 2014.  Full Article

Johnson & Johnson raises FY 2014 earnings guidance
Tuesday, 15 Jul 2014 07:45am EDT 

Johnson & Johnson:Increased FY 2014 earnings guidance to $5.85 - $5.92 per share.Says guidance excludes the impact of special items.FY 2014 EPS of $5.90 - Thomson Reuters I/B/E/S.  Full Article

Plaintiffs’ lawyers reject J&J claims of fraud in mesh lawsuits

NEW YORK - Lawyers for thousands of women suing Johnson & Johnson’s Ethicon Inc over transvaginal mesh devices are fighting back against the company’s claim that illegal phone solicitations may have resulted in baseless lawsuits.

Search Stocks